[{"Physician_Profile_ID": "525937", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Eli Lilly and Company", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IN", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000088", "Total_Amount_of_Payment_USDollars": "262.00", "Date_of_Payment": "10/15/2015", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "263814786", "Name_of_Associated_Covered_Drug_or_Biological1": "", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 WITH A LONG-TERM OPEN-LABEL EXTENSION IN PATIENTS WITH CHRONIC CLUSTER HEADACHE", "Research_Information_Link": "https://clinicaltrials.gov/ct2/show/NCT02438826", "Context_of_Research": "The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."}]